#AS­CO21: As­traZeneca's PD-L1 Imfinzi tacks on 5-year sur­vival da­ta in NSCLC, which it's call­ing 'un­prece­dent­ed'

Amid a sea of com­peti­tors in PD-(L)1, As­traZeneca has looked to out­run the big dogs in Mer­ck and Bris­tol My­ers Squibb with its Imfinzi. One way to dif­fer­en­ti­ate? Long-term ef­fect — and now As­traZeneca has five-year da­ta in NSCLC it thinks can set its drug apart.

Imfinzi post­ed an over­all sur­vival rate of 43% for Stage III non-small cell lung can­cer pa­tients whose tu­mors can’t be re­moved five years af­ter chemora­di­a­tion treat­ment, ac­cord­ing to da­ta from the Phase III PA­CIF­IC study set to be re­leased at this week­end’s #AS­CO21.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.